Pfizer Q2 Results: Profit Rises 6.3%, Misses Estimates
Pfizer's margin expanded 41 basis points to 32.15% in the September quarter.
(Exterior of Pfizer Ltd. head office building in Mumbai. Photographer: Vijay Sartape/NDTV Profit)
Pfizer Ltd.'s net profit rose 6.3% in the second quarter of the financial year, missing analysts' estimates.
The pharmaceutical company posted a profit of Rs 158 crore in the quarter ended September as compared to Rs 149 crore for the same period last year, according to an exchange filing on Monday. Analysts tracked by Bloomberg had a consensus estimate of Rs 169 crore.
The company recorded a revenue of Rs 589 crore for the July–September period, up 2.3% from Rs 575 crore in the second quarter of the previous fiscal. Analysts tracked by Bloomberg had a consensus estimate of Rs 624 crore.
Pfizer posted earnings before interest, taxes, depreciation and amortisation of Rs 189 crore, a 3.6% growth from Rs 183 crore in the year-ago period. Its margin expanded to 32.15% from 31.74%.
Pfizer Q2 FY25 Earnings Highlights (YoY)
Revenue up 2.3% to Rs 589 crore versus Rs 575 crore.
Ebitda up 3.6% to Rs 189 crore versus Rs 183 crore.
Margin expands 41 basis points to 32.15% versus 31.74%.
Net profit up 6.3% to Rs 158 crore versus Rs 149 crore.
Shares of Pfizer closed 0.66% lower at Rs 5,268.55 apiece on the National Stock Exchange, compared to a 0.65% advance in the benchmark Nifty 50. The stock has risen 33.58% in the last 12 months and 23.42% on a year-to-date basis.
Out of the three analysts tracking the company, one has a 'buy' rating on the stock and two recommend 'hold', according to Bloomberg data. The average of 12-month analysts' consensus price target implies a potential upside of 12.6%.
